190 related articles for article (PubMed ID: 24902844)
1. Identification of compounds that selectively target highly chemotherapy refractory neuroblastoma cancer stem cells.
Díaz-Carballo D; Acikelli AH; Bardenheuer W; Gustmann S; Malak S; Stoll R; Kedziorski T; Nazif MA; Jastrow H; Wennemuth G; Dammann P; Feigel M; Strumberg D
Int J Clin Pharmacol Ther; 2014 Sep; 52(9):787-801. PubMed ID: 24902844
[TBL] [Abstract][Full Text] [Related]
2. Flavonoids isolated from Caribbean propolis show cytotoxic activity in human cancer cell lines.
Acikelli AH; Gustmann S; Bardenheuer W; Klein J; Dembinski U; Kohl B; Yip KT; Nazif A; Stoll R; Strumberg D; Díaz-Carballo D
Int J Clin Pharmacol Ther; 2013 Jan; 51(1):51-3. PubMed ID: 23259999
[No Abstract] [Full Text] [Related]
3. Multi-targeted polycyclic polyprenylated acylphloroglucinols are major constituents of Cuban propolis and contributors to its anticancer activity.
Díaz-Carballo D; Gustmann S; Acikelli AH; Bardenheuer W; Klein J; Dembinski U; Kohl B; Yip KT; Nazif A; Stoll R; Strumberg D
Int J Clin Pharmacol Ther; 2013 Jan; 51(1):54-5. PubMed ID: 23260000
[No Abstract] [Full Text] [Related]
4. In vitro and in vivo antitumor activity of the novel derivatized polyvinyl alcohol-based polymer P10(4).
Raffaghello L; Zuccari G; Carosio R; Orienti I; Montaldo PG
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3485-93. PubMed ID: 16740774
[TBL] [Abstract][Full Text] [Related]
5. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
[TBL] [Abstract][Full Text] [Related]
6. The contribution of plukenetione A to the anti-tumoral activity of Cuban propolis.
Díaz-Carballo D; Malak S; Bardenheuer W; Freistuehler M; Peter Reusch H
Bioorg Med Chem; 2008 Nov; 16(22):9635-43. PubMed ID: 18951805
[TBL] [Abstract][Full Text] [Related]
7. Targeted BCL2 inhibition effectively inhibits neuroblastoma tumour growth.
Lamers F; Schild L; den Hartog IJ; Ebus ME; Westerhout EM; Ora I; Koster J; Versteeg R; Caron HN; Molenaar JJ
Eur J Cancer; 2012 Nov; 48(16):3093-103. PubMed ID: 22366560
[TBL] [Abstract][Full Text] [Related]
8. Pseudolaric acid B, a novel microtubule-destabilizing agent that circumvents multidrug resistance phenotype and exhibits antitumor activity in vivo.
Wong VK; Chiu P; Chung SS; Chow LM; Zhao YZ; Yang BB; Ko BC
Clin Cancer Res; 2005 Aug; 11(16):6002-11. PubMed ID: 16115945
[TBL] [Abstract][Full Text] [Related]
9. Tumor apoptosis induced by epoxide-containing piperazines, a new class of anti-cancer agents.
Eilon GF; Gu J; Slater LM; Hara K; Jacobs JW
Cancer Chemother Pharmacol; 2000; 45(3):183-91. PubMed ID: 10663635
[TBL] [Abstract][Full Text] [Related]
10. Novel nontoxic heat shock protein 90 inhibitors having selective antiproliferative effect.
Orosz A; Szabo A; Szeman G; Janaky T; Somlai C; Penke B; Bodor A; Perczel A
Int J Biochem Cell Biol; 2006; 38(8):1352-62. PubMed ID: 16540363
[TBL] [Abstract][Full Text] [Related]
11. Down-regulation of insulin-like growth factor I receptor activity by NVP-AEW541 has an antitumor effect on neuroblastoma cells in vitro and in vivo.
Tanno B; Mancini C; Vitali R; Mancuso M; McDowell HP; Dominici C; Raschellà G
Clin Cancer Res; 2006 Nov; 12(22):6772-80. PubMed ID: 17121898
[TBL] [Abstract][Full Text] [Related]
12. Zoledronate sensitizes neuroblastoma-derived tumor-initiating cells to cytolysis mediated by human γδ T cells.
Nishio N; Fujita M; Tanaka Y; Maki H; Zhang R; Hirosawa T; Demachi-Okamura A; Uemura Y; Taguchi O; Takahashi Y; Kojima S; Kuzushima K
J Immunother; 2012 Oct; 35(8):598-606. PubMed ID: 22996365
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of class I and II vs class III histone deacetylase inhibitors in neuroblastoma.
Lautz TB; Naiditch JA; Clark S; Chu F; Madonna MB
J Pediatr Surg; 2012 Jun; 47(6):1267-71. PubMed ID: 22703804
[TBL] [Abstract][Full Text] [Related]
14. Tideglusib attenuates growth of neuroblastoma cancer stem/progenitor cells in vitro and in vivo by specifically targeting GSK-3β.
Bahmad HF; Chalhoub RM; Harati H; Bou-Gharios J; Assi S; Ballout F; Monzer A; Msheik H; Araji T; Elajami MK; Ghanem P; Chamaa F; Kadara H; Abou-Antoun T; Daoud G; Fares Y; Abou-Kheir W
Pharmacol Rep; 2021 Feb; 73(1):211-226. PubMed ID: 33030673
[TBL] [Abstract][Full Text] [Related]
15. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
16. The novel atypical retinoid ST1926 is active in ATRA resistant neuroblastoma cells acting by a different mechanism.
Di Francesco AM; Meco D; Torella AR; Barone G; D'Incalci M; Pisano C; Carminati P; Riccardi R
Biochem Pharmacol; 2007 Mar; 73(5):643-55. PubMed ID: 17150196
[TBL] [Abstract][Full Text] [Related]
17. A potential target associated with both cancer and cancer stem cells: a combination therapy for eradication of breast cancer using vinorelbine stealthy liposomes plus parthenolide stealthy liposomes.
Liu Y; Lu WL; Guo J; Du J; Li T; Wu JW; Wang GL; Wang JC; Zhang X; Zhang Q
J Control Release; 2008 Jul; 129(1):18-25. PubMed ID: 18466993
[TBL] [Abstract][Full Text] [Related]
18. Chemical constituents of Brazilian propolis and their cytotoxic activities.
Banskota AH; Tezuka Y; Prasain JK; Matsushige K; Saiki I; Kadota S
J Nat Prod; 1998 Jul; 61(7):896-900. PubMed ID: 9677271
[TBL] [Abstract][Full Text] [Related]
19. Preclinical antitumor activity of the oral platinum analog satraplatin.
Wosikowski K; Lamphere L; Unteregger G; Jung V; Kaplan F; Xu JP; Rattel B; Caligiuri M
Cancer Chemother Pharmacol; 2007 Sep; 60(4):589-600. PubMed ID: 17541592
[TBL] [Abstract][Full Text] [Related]
20. Polo-like kinase 1 is a therapeutic target in high-risk neuroblastoma.
Ackermann S; Goeser F; Schulte JH; Schramm A; Ehemann V; Hero B; Eggert A; Berthold F; Fischer M
Clin Cancer Res; 2011 Feb; 17(4):731-41. PubMed ID: 21169242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
